Ning Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5298116/publications.pdf

Version: 2024-02-01

304602 302012 1,672 62 22 39 citations h-index g-index papers 64 64 64 1623 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The effects and possible mechanism of action of apolipoprotein M on the growth of breast cancer cells. Molecular Biology Reports, 2022, 49, 1171-1179.	1.0	5
2	Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages. FEBS Open Bio, 2021, 11, 1607-1620.	1.0	6
3	Apolipoprotein M promotes growth and inhibits apoptosis of colorectal cancer cells through upregulation of ribosomal protein S27a. EXCLI Journal, 2021, 20, 145-159.	0.5	3
4	Insulin Resistance in Apolipoprotein M Knockout Mice is Mediated by the Protein Kinase Akt Signaling Pathway. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 771-780.	0.6	3
5	Comprehensive lipidomics in apoM mice reveals an overall state of metabolic distress and attenuated hepatic lipid secretion into the circulation. Journal of Genetics and Genomics, 2020, 47, 523-534.	1.7	6
6	Non-negligible factors in studying the ApoM-S1P axis using EA.hy926 cells. Annals of Translational Medicine, 2020, 8, 383-383.	0.7	1
7	ApolipoproteinÂM overexpression through adenoâ€associated virus gene transfer improves insulin secretion and insulin sensitivity in Gotoâ€Kakizaki rats. Journal of Diabetes Investigation, 2020, 11, 1150-1158.	1.1	8
8	Apolipoprotein M promotes the anti-inflammatory effect of high-density lipoprotein by binding to scavenger receptor Bl. Annals of Translational Medicine, 2020, 8, 1676-1676.	0.7	8
9	Increased expression levels of inflammatory cytokines and adhesion molecules in lipopolysaccharide‑induced acute inflammatory apoM‑/‑ mice. Molecular Medicine Reports, 2020, 22, 3117-3126.	1.1	5
10	Apolipoprotein M: Research Progress and Clinical Perspective. Advances in Experimental Medicine and Biology, 2020, 1276, 85-103.	0.8	4
11	eGFR, cystatin C and creatinine in shrunken pore syndrome. Clinica Chimica Acta, 2019, 498, 1-5.	0.5	14
12	Expression of fITF and asTF splice variants in various cell strains and tissues. Molecular Medicine Reports, 2019, 19, 2077-2086.	1.1	3
13	<p>Apolipoprotein M could inhibit growth and metastasis of SMMC7721 cells via vitamin D receptor signaling</p> . Cancer Management and Research, 2019, Volume 11, 3691-3701.	0.9	18
14	Apolipoprotein M induces inhibition of inflammatory responses via the S1PR1 and DHCR24 pathways. Molecular Medicine Reports, 2019, 19, 1272-1283.	1.1	10
15	Apolipoprotein M Protects Against Lipopolysaccharide-Induced Acute Lung Injury via Sphingosine-1-Phosphate Signaling. Inflammation, 2018, 41, 643-653.	1.7	18
16	Detection of simultaneous multi-mutations using base-quenched probe. Analytical Biochemistry, 2018, 543, 79-81.	1.1	6
17	Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways. Biochemical and Biophysical Research Communications, 2018, 501, 520-526.	1.0	21
18	Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Frontiers in Pharmacology, 2018, 9, 352.	1.6	10

#	Article	IF	CITATIONS
19	Increased apolipoprotein M induced by lack of scavenger receptor BI is not activated via HDL-mediated cholesterol uptake in hepatocytes. Lipids in Health and Disease, 2018, 17, 200.	1.2	7
20	$17\hat{l}^2$ -estradiol regulates the expression of apolipoprotein M through estrogen receptor \hat{l} ±-specific binding motif in its promoter. Lipids in Health and Disease, 2017, 16, 66.	1.2	6
21	Apolipoprotein M gene single nucleotide polymorphisms discovery in patients with chronic obstructive pulmonary disease and determined by the base-quenched probe technique. Gene, 2017, 637, 9-13.	1.0	4
22	Apolipoprotein M increases the expression of vitamin D receptor mRNA in colorectal cancer cells detected with duplex fluorescence reverse transcription-quantitative polymerase chain reaction. Molecular Medicine Reports, 2017, 16, 1167-1172.	1.1	13
23	Increased CXCL8 Expression Is Negatively Correlated with the Overall Survival of Patients with ER-Negative Breast Cancer. Anticancer Research, 2017, 37, 4845-4852.	0.5	10
24	miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget, 2016, 7, 16205-16216.	0.8	109
25	βâ€glucan restores tumorâ€educated dendritic cell maturation to enhance antitumor immune responses. International Journal of Cancer, 2016, 138, 2713-2723.	2.3	41
26	Association between the ABCC11 gene polymorphism and the expression of apolipoprotein D by the apocrine glands in axillary osmidrosis. Molecular Medicine Reports, 2015, 11, 4463-4467.	1.1	6
27	Hyperglycemia-induced downregulation of apolipoprotein M expression is not via the hexosamine pathway. Lipids in Health and Disease, 2015, 14, 110.	1.2	5
28	Decreased Splenic <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msup><mml:mrow><mml:mtext>CD4</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mr< td=""><td>nmloræext:</td><td>>+&mml:mtex</td></mml:mr<></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math>	nml oræ ext:	>+&mml:mtex
29	Increased mRNA levels of apolipoprotein M and apolipoprotein Al in the placental tissues with fetal macrosomia. Archives of Gynecology and Obstetrics, 2015, 291, 299-303.	0.8	3
30	Rosiglitazone Enhances Apolipoprotein M (<i>Apom</i>) Expression in Rat's Liver. International Journal of Medical Sciences, 2014, 11, 1015-1021.	1.1	16
31	Decreased Activities of Apolipoprotein M Promoter Are Associated with the Susceptibility to Coronary Artery Diseases. International Journal of Medical Sciences, 2014, 11, 365-372.	1.1	12
32	Palmitic acid suppresses apolipoprotein M gene expression via the pathway of PPARβ \hat{l} ′ in HepG2 cells. Biochemical and Biophysical Research Communications, 2014, 445, 203-207.	1.0	15
33	A novel method of detecting alpha-1 antitrypsin deficiency of Z mutant (GAG342AAG) in a single PCR reaction using base-quenched probe. Clinica Chimica Acta, 2014, 427, 29-33.	0.5	7
34	Intralipid Decreases Apolipoprotein M Levels and Insulin Sensitivity in Rats. PLoS ONE, 2014, 9, e105681.	1.1	15
35	ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells. Biochemical and Biophysical Research Communications, 2012, 421, 152-156.	1.0	21
36	Estrogen upregulates hepatic apolipoprotein M expression via the estrogen receptor. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 1146-1151.	1.2	13

#	Article	IF	Citations
37	Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochemica, 2011, 113, 53-57.	0.9	17
38	TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells. Lipids in Health and Disease, 2011, 10, 199.	1.2	12
39	Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochemica, 2010, 112, 233-239.	0.9	33
40	A novel method of detecting mitochondrial m.1494C>T and m.1555A>G mutations in a single PCR reaction using base-quenched probe. Clinica Chimica Acta, 2010, 411, 2114-2116.	0.5	6
41	Expression and localization of apolipoprotein M in human colorectal tissues. Lipids in Health and Disease, 2010, 9, 102.	1.2	28
42	Genotyping of single nucleotide polymorphisms using base-quenched probe: A method does not invariably depend on the deoxyguanosine nucleotide. Analytical Biochemistry, 2009, 386, 161-166.	1.1	33
43	Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2009, 8, 25-8.	0.6	7
44	Side effects during treatment of advanced gastric carcinoma by chemotherapy combined with CIK-cell transfusion in elderly people. Chinese Journal of Clinical Oncology, 2008, 5, 79-82.	0.0	3
45	Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. Lipids in Health and Disease, 2008, 7, 25.	1.2	26
46	Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochemical and Biophysical Research Communications, 2008, 371, 114-117.	1.0	41
47	Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 879-882.	1.2	40
48	Lipids changes in liver cancer. Journal of Zhejiang University: Science B, 2007, 8, 398-409.	1.3	57
49	Metabolism of high density lipoproteins in liver cancer. World Journal of Gastroenterology, 2007, 13, 3159.	1.4	9
50	Influence of liver cancer on lipid and lipoprotein metabolism. Lipids in Health and Disease, 2006, 5, 4.	1.2	151
51	Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 256-260.	1.2	27
52	Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. Biochemical and Biophysical Research Communications, 2006, 342, 1174-1177.	1.0	31
53	Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1734, 198-202.	1.2	33
54	Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. Journal of Nutritional Biochemistry, 2004, 15, 579-582.	1.9	40

#	Article	IF	CITATION
55	Apolipoprotein M. Lipids in Health and Disease, 2004, 3, 21.	1.2	42
56	Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1683, 33-37.	1.2	40
57	Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochemical and Biophysical Research Communications, 2004, 321, 916-921.	1.0	57
58	Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochemica, 2004, 106, 123-128.	0.9	35
59	Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochemica, 2003, 105, 67-72.	0.9	86
60	Effects of Platelet-Activating Factor, Tumor Necrosis Factor, and Interleukin- $1\hat{1}\pm$ on the Expression of Apolipoprotein M in HepG2 Cells. Biochemical and Biophysical Research Communications, 2002, 292, 944-950.	1.0	51
61	ACTH Decreases the Expression and Secretion of Apolipoprotein B in HepG2 Cell Cultures. Journal of Biological Chemistry, 2001, 276, 38680-38684.	1.6	24
62	A Novel Human Apolipoprotein (apoM). Journal of Biological Chemistry, 1999, 274, 31286-31290.	1.6	282